Pharmacological blockade of platelet GPIIb/IIIa and the inherited disorders of the platelet GPIIb/IIIa (Glanzmann's thrombasthenia): how safe is this antithrombotic approach for both acute and chronic treatment of thromboembolic disorders? Brief communication.
Mousa
S A
SA
Du Pont Merck Pharmaceutical Company, Cardiovascular Diseases Research, Wilmington, Del 19880-0400.
Reilly
T M
TM
D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D013915:Thrombasthenia / Q000097:blood / Q000139:chemically induced* / Q000235:genetics; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy* / Q000235:genetics
D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins